 SOUTH SAN FRANCISCO, Calif., March 16, 2021 GLOBE NEWSWIRE -- Akero Therapeutics, Inc. Nasdaq: AKRO, a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis NASH, today reported fourth quarter and full year financial results for the period ending December 31, 2020. 